Literature DB >> 28065708

An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems.

Rolf Wachter1, Marcel Halbach2, George L Bakris3, John D Bisognano4, Hermann Haller5, Joachim Beige6, Abraham A Kroon7, Mitra K Nadim8, Eric G Lovett9, Jill E Schafer10, Peter W de Leeuw7.   

Abstract

Baroreflex activation therapy (BAT) is a device-based therapy for patients with treatment-resistant hypertension. In a randomized, controlled trial, the first-generation system significantly reduced blood pressure (BP) versus sham. Although an open-label validation study of the second-generation system demonstrated similar BP reductions, controlled data are not presently available. Therefore, this investigation compares results of first- and second-generation BAT systems. Two cohorts of first-generation BAT system patients were generated with propensity matching to compare against the validation group of 30 second-generation subjects. The first cohort was drawn from the first-generation randomized trial sham group and the second cohort from the active therapy group. Safety and efficacy were compared for the second-generation group relative to the first generation. At 6 months, second-generation BAT outperformed first-generation sham systolic BP reduction by 20 ± 28 mm Hg (mean ± standard deviation, P = .008), while BP reduction in first- and second-generation active groups was similar. At 12 months, efficacy was comparable between all three groups after the sham group had received 6 months of therapy; 47% of second-generation patients achieved goal systolic BP of 140 mm Hg or less after 12 months, comparable to 50% of patients at goal in the first-generation group (P > .999). Implant procedure time, system/procedural safety, and pulse generator longevity improved with the second-generation system. Propensity-matched cohort analysis of the first- and second-generation BAT systems suggests similar therapeutic benefit and superior BP reduction of the second-generation system relative to sham control. Implantation procedure duration and perioperative safety were improved with the second-generation device. These findings should be validated in a prospective randomized trial.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autonomic nervous system; baroreflex; resistant hypertension; sham control

Mesh:

Substances:

Year:  2016        PMID: 28065708     DOI: 10.1016/j.jash.2016.12.003

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  8 in total

Review 1.  [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].

Authors:  M Wallbach; M J Koziolek; R Wachter
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

2.  [Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017].

Authors:  M Koziolek; J Beige; M Wallbach; D Zenker; G Henning; M Halbach; N Mader; F Mahfoud; G Schlieper; V Schwenger; M Hausberg; J Börgel; M Lodde; M van der Giet; J Müller-Ehmsen; J Passauer; S Parmentier; S Lüders; B K Krämer; S Büttner; F Limbourg; J Jordan; O Vonend; H-G Predel; H Reuter
Journal:  Internist (Berl)       Date:  2017-10       Impact factor: 0.743

Review 3.  Device-based therapies for arterial hypertension.

Authors:  Lucas Lauder; Michel Azizi; Ajay J Kirtane; Michael Böhm; Felix Mahfoud
Journal:  Nat Rev Cardiol       Date:  2020-04-14       Impact factor: 32.419

4.  Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system.

Authors:  Manuel Wallbach; Ellen Born; Deborah Kämpfer; Stephan Lüders; Gerhard A Müller; Rolf Wachter; Michael J Koziolek
Journal:  Clin Res Cardiol       Date:  2019-08-06       Impact factor: 5.460

5.  Pressure overload promotes cystatin C secretion of cardiomyocytes to regulate the MAPK signaling pathway and mediate cardiac hypertrophy.

Authors:  Yi Shen; Xiaoyi Zhang; Chenguang Li; Xiang Wang; Yong Ye; Jie Yuan; Hui Gong; Yunzeng Zou; Junbo Ge
Journal:  Ann Transl Med       Date:  2020-11

6.  Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology.

Authors:  Asife Sahinarslan; Emine Gazi; Meryem Aktoz; Cigdem Ozkan; Gülay Ulusal Okyay; Ozgul Ucar Elalmis; Erdal Belen; Reviewers Atila Bitigen; Ulver Derici; Neslihan Bascil Tutuncu; Aylin Yildirir
Journal:  Anatol J Cardiol       Date:  2020-09       Impact factor: 1.596

Review 7.  Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases.

Authors:  Le Li; Zhao Hu; Yulong Xiong; Yan Yao
Journal:  Front Cardiovasc Med       Date:  2021-12-09

8.  Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension.

Authors:  Ann-Kathrin Schäfer; Tim Kuczera; Rebecca Wurm-Kuczera; Dieter Müller; Ellen Born; Mark Lipphardt; Marlene Plüss; Manuel Wallbach; Michael Koziolek
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-06-08       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.